Genzyme Tries to Convince Sanofi-Aventis Its MS Drug Is Worth More

Biotechnology company Genzyme (GENZ) is holding an analyst and investor meeting Monday focused on the commercial potential of its multiple sclerosis (MS) drug Campath. It's part of Genzyme's attempt to convince Sanofi-Aventis (SNY) that it's worth more than the Paris-based pharmaceutical giant has been offering.

Sanofi and Cambridge, Mass.-based Genzyme have been butting heads for five months in acquisition negotiations. Last week, the French company extended its hostile takeover bid of $69 a share, or $18.5 billion in cash, for the U.S. company by six weeks. But the companies seemed far apart on price as ever.

Same Drug, Higher Price?

Genzyme has previously said that its Campath could generate peak annual sales of at least $3 billion. But Sanofi projects that number as closer to $700 million. Independent analysts put the figure somewhere in the middle, according to Reuters. Of course, this affect multiples. Under Sanofi's assumption, the multiples are very competitive at 18.5 times long-term earnings and 4.2 times long-term sales. These multiples take a hit under Genzyme's projections.

One problem is that Campath, known generically as alemtuzumab, already brings in $110 million in annual sales as a cancer drug, but at a much lower price per dose than currently marketed MS drugs. But the rare-disease drugmaker has said it believes it could sell the drug at a higher price as a MS treatment, possibly by giving Campath away to cancer patients.

One option mentioned for addressing all these unknowns in the context of a merger is the use of contingent value rights: Genzyme shareholders could receive additional compensation later based on the future performance of Campath.

While that's the direction many believe this is going, Sanofi would still need to increase its bid slightly, analysts believe, to seal the deal. Previously, analysts said they believed an agreement would be reached at between $75 and $80 a share. But with a contingent value rights plan in place, a deal might be reached for a share price in the low $70s.

Update: In the two-hour presentation, Genzyme shared internal and independent, third-party analyses that support its expectations of peak sales of roughly $3 billion to $3.5 billion within five years of Campath's launch. The company expects to file for U.S. and EU approval in early 2012, and has been granted fast-track status by the FDA. Still, Genzyme shares fell 0.2%, closing below $70 at $69.65. It seems the company wasn't that convincing.



Increase your money and finance knowledge from home

Professional Vs Do it Yourself Investing

Should you get advice or DYI?

View Course »

Income Investing

Grow your nest-egg.

View Course »

Add a Comment

*0 / 3000 Character Maximum

5 Comments

Filter by:
Gumby

My 5 options on GEnz will expire on Jan 21 2011 the same day SAnofi offer will end! What a coinicidence!~

December 20 2010 at 7:06 PM Report abuse rate up rate down Reply
Gumby

Maybe someone will offer $85 for Genz next year or two. Why now with all the confusion over the cleaning efforts in the contaminated plants? Reject Sanofi !

December 20 2010 at 7:05 PM Report abuse rate up rate down Reply
Gumby

If $69 price is right for now, what about five years later or ten years later? $200 or $500? Genz is getting ripe for the plucking. Screw Sanofi!!

December 20 2010 at 7:04 PM Report abuse rate up rate down Reply
Bob

Carol hit the nail squarely on its head!

December 20 2010 at 1:56 PM Report abuse rate up rate down Reply
Carol

So, in the ideal scenario, you should try for cancer if you have MS. Interesting to read how easily they play with the lives of the afflicted, no? Of course, medications should be priced as high as possible so the pharma companies can achieve healthy profits.

December 20 2010 at 1:17 PM Report abuse +1 rate up rate down Reply